Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Costs In Contemporary Transplant Practice
M. Wyld, T. Ying, K. Wyburn, S. Chadban
Renal Department, Royal Prince Alfred Hospital, Camperdown, Australia
*Purpose: The cost of kidney transplantation, in the context of increasing immunological and medical complexity and higher donor and recipient age, remains uncertain. In 2009,…
2019 American Transplant Congress
Evaluating Hepatitis C Treatment after Solid Organ Transplantation
A. J. Burgos¹, R. Yau¹, C. Tunwar², J. A. Goss³, S. Khaderi³, N. L. Sussman⁴
¹Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ²CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ³Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, ⁴Abdominal Transplant & Liver Disease, Baylor College of Medicine, Houston, TX
*Purpose: There is limited data on the use of direct acting antivirals for hepatitis C virus (HCV) in the solid organ transplant (SOT) population. The…
2019 American Transplant Congress
Genome-Wide Profiling of BK Polyomavirus Integration in Urothelial Carcinoma of Kidney Transplant Recipients Reveals a Potential Microhomology or Nonhomologous End Joining Mediated Integration Mechanism
Y. Jin¹, Y. Zhou¹, W. Deng¹, R. Lee², Y. Liu¹, M. Blute³, R. Liu¹, N. Elias⁴, F. Fu¹, B. Guan¹, J. Geng¹, J. Ma⁵, J. Zhou⁵, N. Liu⁵, C. Wu⁶, Y. Miao¹
¹Nanfang Hospital, Southern Medical University, Guangdzhou, China, ²Departments of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Departments of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Departments of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Mygenostics Co., Beijing, China, ⁶Departments of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
*Purpose: Chronic BK polyomavirus (BKV) infection is recognized as a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients. Besides, a positive correlation…
2019 American Transplant Congress
Bcl-2/Bcl-xL Inhibition by Navitoclax vs. Bcl-2 Alone Inhibition by Venetoclax for Induction of Mixed Chimerism in Non-Human Primates
H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, I. Rosales², B. Cosimi¹, P. Cippa³, T. Fehr³, T. Kawai¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Medicine, University of Zurich, Zurich, Switzerland
*Purpose: We recently demonstrated that a specific Bcl-2 inhibitor, Venetoclax, can promote mixed chimerism and renal allograft tolerance in non-human primates (NHPs) with reduced myelosuppressive…
2018 American Transplant Congress
Predicting Survival after Deceased-Donor Kidney Transplants by Donor-Recipient Match: Who Can Tolerate a High-KDPI Kidney?
S. Bae, J. Garonzik Wang, K. Jackson, A. Thomas, X. Luo, A. Massie, D. Segev.
Johns Hopkins School of Medicine, Baltimore, MD.
Deceased-donor kidney transplantation (DDKT) with high-KDPI kidneys carries an additional risk of mortality and graft failure, which could be tolerable for some candidates but detrimental…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
2018 American Transplant Congress
Redo Kidney Transplant in FSGS
J. Verbesey, A. Javaid, S. Yi, G. Vranic, A. Gilbert, P. Abrams, S. Ghasemian, J. Moore, B. Thomas, M. Cooper, B. Javaid.
Kidney and Pancreas Transplant Program, MedStar Georgetown Transplant Institute, Washington, DC.
Objective: Analyze risk of graft failure due to recurrent FSGS in patients with prior failed kidney transplants under consideration for a subsequent transplant.Results: We identified…
2018 American Transplant Congress
Prevalence of Frailty among Kidney Transplant Recipients in the United States
A. Thomas,¹ A. Shaffer,¹ H. Ying,¹ S. Norman,² D. Segev,¹ M. McAdams-DeMarco.¹
¹JHU, Baltimore; ²University of Michigan, Ann Arbor.
Frailty, a measure of physiologic reserve, increases the risk of delayed graft function, longer length of stay, early hospital readmission, immunosuppression intolerance, and mortality among…
2018 American Transplant Congress
Anti-TIRC7 Antibody Acts Synergistically with Tacrolimus in Promoting Graft Survival in a Rat Kidney Transplant Model
S. Tullius,¹ Y. Kumamoto,² U. Nalan.³
¹Department of Medicine, Brigham and Women's Hospital, Boston, MA; ²Department of Surgery, Kitasato University School of Medicine, Kanagawa, Sagamihara, Japan; ³Institute for Medical Immunology, University Hospital Charite, Berlin, Germany.
Background: Induction of T cell immune response c-DNA (TIRC7) is restricted to activated lymphocytes. Modulation of TIRC7 signalling prevents immune activation specifically at the site…
2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
J. Choi,¹ O. Aubert,² S. Louie,¹ N. Ammerman,¹ A. Vo,¹ A. Peng,¹ E. Huang,¹ R. Najjar,¹ D. Puliyanda,¹ S. Sethi,¹ M. Haas,¹ K. Lim,¹ A. Loupy,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Translational Center for Organ Transplantation, Paris, France.
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…